Melanoma loss of IFN-g signaling is a major mechanism of resistance to immune checkpoint blockers such as anti-CTLA-4 and anti-PD-1, a prominent type of immunotherapies offering unprecedented therapeutic hopes to melanoma patients. However, strategies of overcoming this resistance have been elusive.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us